Session: FRI 368-390-Metabolic Bone Disease Case Reports (posters)
Poster Board FRI 382
Fibroblast Growth Factor 23 (FGF23) is a phosphaturic hormone. Rarely FGF 23 is produced by soft tissue mesenchymal tumors causing hypophosphatemic osteomalacia.
A 79 year old male was referred with a 12 month history of bone pain. Initial investigation noted severe hypophosphatemia with serum phosphate of 7.2mg/dL (14-27) and raised urinary phosphate 185mg/dL/day (44.8-134.4). Corrected and ionised calcium level were normal. Further investigation demonstrated an inappropriately normal 1,25 vitamin D level 2.7ug/dL (2.1-7.5) and normal PTH 0.49ng/dL (0.1-0.5). His rib, left knee and ankle pain was evaluated with a bone scan that demonstrated multiple minimal trauma fractures. Screening for secondary causes of osteoporosis was otherwise unremarkable. PET Ga-68 Dotate scan showed an intensely avid lesion overlying the dorsum of the foot that was confirmed on further MRI imaging to be overlying the tibialis anterior.
One tablet three times day of sandoz phosphate and two tablets a day of Calcitriol were commenced with improvement in his symptoms and serum phosphate. Excision of the lesion confirmed a soft tissue mesenchymal tumor that stained positively for FGF23. Following resection of the tumor his oral phosphate and vitamin D supplementation was ceased. He remained asymptomatic with normal electrolytes.
Mesenchymal tumors that produce FGF23 should be considered as a rare cause of osteomalacia if associated with hypophosphatemia and raised urinary phosphate in patients with bone pain or minimal trauma fractures.
Nothing to Disclose: LC, JYY, LR, AKS
*Please take note of The Endocrine Society's News Embargo Policy at https://www.endocrine.org/news-room/endo-annual-meeting/pr-resources-for-endo
See more of: Abstracts - Orals, Poster Previews, and Posters